Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Elucid Bioimaging
AddedFeb 15, 2024
UpdatedJun 18, 2026
Elucid Bioimaging

Elucid Bioimaging

Series C

Elucid, a US-based med-tech firm, enhances vascular diagnostic imaging accuracy and affordability using AI.

HQ
Boston, MA, US
Founded
2013
Overview
Compare
Fundraising
Employees

Elucid Bioimaging is a US-based medical technology company focused on enhancing the accuracy and affordability of vascular diagnostic imaging through advanced AI. Their core mission is to leverage machine intelligence to improve diagnostic precision, patient experience, and cost-effectiveness in vascular health. Elucid offers cutting-edge imaging solutions that cater to healthcare providers and patients, aiming to revolutionize the field of vascular diagnostics.

Elucid has made significant strides in the med-tech industry, earning recognition for its innovative use of AI in medical imaging. Their technology has been adopted by leading healthcare institutions, contributing to improved diagnostic outcomes and patient care. The company's impact is marked by its commitment to advancing medical diagnostics and making high-quality healthcare more accessible.

Elucid Bioimaging - Quick Facts

When was Elucid Bioimaging founded?

Elucid Bioimaging was founded in 2013.

Where is Elucid Bioimaging's headquarters located?

Elucid Bioimaging's headquarters is located in Boston, MA, US.

When was Elucid Bioimaging's last funding round?

Elucid Bioimaging's most recent funding round was for $80M (USD) in November 2023.

How much has Elucid Bioimaging raised to-date?

As of Nov 9, 2023, Elucid Bioimaging has raised a total of $129.7M (USD).

How many employees does Elucid Bioimaging have?

Elucid Bioimaging has 73 employees as of Feb 4, 2024.

Elucid Bioimaging - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medical Imaging
Tags
  • AI Operations
  • Healthtech
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software
ISIC
  • 7210Research and experimental development on natural sciences and engineering
Show 18 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 541510Computer Systems Design and Related Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 541511Custom Computer Programming Services
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7371Computer Programming Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research